Alimera Sciences Inc (ALIM)

[rancher64]

Practically No dilution-expecting Record Revenue & path to profitability from 2H-2016 onwards

Raising $25M cash for 18.9M new shares. Do your DD folks.. Such type of fund raised for a small biotech with no approved product, no sales but only trial - would give investors only a dilution - nothing else. But ALIM has a hot selling unique product at a demanding market place and this cash will only move ALIM faster towards sales growth and profitability. ALIM could post operational breakeven at $15M quarterly revenue and its US sales growing at a huge 70% to 80% rate. $15M quarterly revenue is just around the corner - could come as early as Q4-2016. That's what management looking for - positive EBITDA in 2016 and solid cash flow in 2017.

ILUVIEN's potential is huge - it could be a billion dollar blockbuster drug candidate and a buyout target. This new 18.9M shares practically can't create any dent to the stock price. Great accumulation, great loading point here. Q3 sales will again beat the analysts' expectation by large margin. ILUVIEN is miles ahead than its competitors in efficacy, safety, administration and pricing.